Floatz logo

MONOCLONAL ANTIBODY BC8

Myelogenous Leukemia

Actinium Pharmaceuticalsmonoclonal_antibodyPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Rapamycin
Masonic Cancer Center, University of Minnesota
Phase 2BB
TACROLIMUS
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2BB
Evomela
Dana-Farber Cancer Institute
Phase 2B
Posaconazole
AbbVie
Phase 1CC
mk0752
Merck Sharp & Dohme LLC
Phase 1CC

Same molecule, other indications

MONOCLONAL ANTIBODY BC8 is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
B
Indicative ·
60 / 100
View asset →
myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →